asthma exercise induced bronchoconstriction leukotriene receptor antagonist
Conditions
Interventions
8 weeks of treatment with montelukast.
Sponsors
dr. B.J. Thio
Medisch Spectrum Twente
Afdeling kindergeneeskunde
Haaksbergerstraat 55, 7513 ER Enschede
Postadres: Postbus 50.000, 7500 KA Enschede
Tel: (053)-4872310
Email: B.Thio@ziekenhuis-mst.nl
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age between 12-18 years; 2. Clinical history of allergic asthma and exercise induced bronchoconstriction; 3. Ability to perform reproducible lung function tests, i.e. coefficient of the predicted value variation in 3 of 5 consecutive measurements 70% of predicted value.
Exclusion criteria
Exclusion criteria: 1. Other pulmonary or cardiac illnesses; 2. Maximal FEV1 < 70% of predicted value; 3. Use of systemic corticosteroids, antihistamines, cromoglycates, anticholinergics in two weeks prior to or during the study; 4. Use of long acting bronchodilator agents 24 hours before testing; 5. Use of short acting bronchodilator agents 8 hours before testing; 6. Hospitalization due to asthma exacerbation in past month; 7. Other medication changes during treatment period; 8. Upper or lower respiratory tract infections during treatment period; 9. Deviation of the FEV1 before the subsequent exercise challenges of more than 12 % from baseline FEV1.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation between change in postexercise fall in FEV1 after a single dose and after 8 weeks of treatment with montelukast. | — |
Secondary
| Measure | Time frame |
|---|---|
| The predictive value for a response to montelukast after 8 weeks of treatment (defined as ΔFEV1 < 15%) of: 1. Baseline FEV1; 2. Symptom score on ACT; 3. IgE; 4. Positive RAST test. | — |
Contacts
Public ContactE.T.G. Kersten
Postbus 50.000
Outcome results
None listed